Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer's disease (BenfoTeam).

<h4>Background</h4>Benfotiamine provides an important novel therapeutic direction in Alzheimer's disease (AD) with possible additive or synergistic effects to amyloid targeting therapeutic approaches.<h4>Objective</h4>To conduct a seamless phase 2A-2B proof of concept tr...

Full description

Saved in:

Bibliographic Details
Main Authors:	Howard H Feldman, José A Luchsinger, Gabriel C Léger, Curtis Taylor, Diane M Jacobs, David P Salmon, Steven D Edland, Karen Messer, Carolyn Revta, Sarah A Flowers, Kerry S Jones, Albert Koulman, Kevin E Yarasheski, Philip B Verghese, Venky Venkatesh, Henrik Zetterberg, January Durant, Jody-Lynn Lupo, Gary E Gibson, ADCS BenfoTeam Study Group
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2024-01-01
Series:	PLoS ONE
Online Access:	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0302998&type=printable
Tags:	Add Tag No Tags, Be the first to tag this record!

Internet

https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0302998&type=printable

Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer's disease (BenfoTeam).

Internet

Similar Items